GlobeNewswire by notified

U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

Share
  • Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccine, bringing deliveries in 2022 and 2023 to a total of nearly 7 million doses
  • Filling capacity is being expanded with a U.S. based contract manufacturer who will fill the vaccines using existing bulk vaccine from previous orders from BARDA
  • Tech transfer to the contract manufacturer and manufacturing planned for 2022
  • Company upgrades its financial guidance for 2022

COPENHAGEN, Denmark, July 15, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox.

The new order follows two previous orders from BARDA in June and July 2022 for 500,000 and 2.5 million doses respectively which, together with an order from BARDA in 2020 for 1.4 million doses, will bring the total deliveries in 2022 and 2023 to nearly 7 million doses.

This additional order will be filled at a U.S. based contract manufacturer using bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic. A tech transfer of the process to the contract manufacturer will begin immediately, with the aim to manufacture all doses under this contract in 2022.

Paul Chaplin, President and CEO of Bavarian Nordic said: “Expanding our manufacturing capabilities into the United States allows Bavarian Nordic to deliver more monkeypox vaccines to meet the immediate worldwide demand for JYNNEOS. This quick response to a serious health crisis is only possible because of the U.S. government’s diligent long-term planning for their national preparedness.”

For the purpose of the Company’s financial guidance for 2022, and due to the accelerated tech transfer process, it is assumed that approximately 1 million doses of this order will be delivered and revenue recognized in 2022. As a consequence and due to other monkeypox orders, Bavarian Nordic raises its expectations for the financial results for 2022 with revenue now expected to be between DKK 2,300 and 2,500 million (previously between DKK 1,900 and 2,100 million), EBITDA expectations raised to a loss between DKK 400 and 600 million (previously a loss between DKK 600 and 800 million) and cash and cash equivalents at year-end now between DKK 1,700 and 1,900 million (previously between DKK 1,500 and 1,700 million).

About our vaccine contracts with the U.S. government
Since 2003, Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine to ensure all populations can be protected from smallpox, including people with weakened immune systems who are at high risk of adverse reactions to traditional smallpox vaccines, which are based on replicating vaccinia virus strains. The Company has supplied nearly 30 million doses of the liquid-frozen version to the U.S., with the vast majority being delivered for emergency use - and now expired - before approval of the vaccine by the FDA in 2019, which included an approval for the monkeypox indication as the only vaccine having obtained this to-date.

BARDA has supported the development of a freeze-dried version of the vaccine with longer shelf-life to replace the stockpile and in 2017 awarded the Company a ten-year contract for supply of freeze-dried vaccines. Under this contract Bavarian Nordic has produced bulk vaccine, corresponding to approximately 13 million doses for future delivery. While the bulk vaccine has already been invoiced, the final drug production of the vaccines (formulation, filling and freeze-drying) will occur from 2023 and onwards. In May 2022, BARDA exercised the first contract options for conversion of the bulk vaccine to freeze-dried doses, anticipated for delivery in 2023-2025. In light of the current global monkeypox outbreak, BARDA has also exercised options for manufacturing of the liquid-frozen formulation of the vaccine for delivery in 2022 and 2023.

This project has been supported in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700019C.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 26 / 2022

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Graduate Management Admission Council Appoints Joy Jones as Incoming CEO8.8.2022 18:00:00 CEST | Press release

Jones to succeed Sangeet Chowfla as head of the global association representing leading graduate business schools RESTON, Va., Aug. 08, 2022 (GLOBE NEWSWIRE) -- The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today announced the appointment of Joy Jones as the organization’s CEO-Elect. Jones currently serves as GMAC’s chief product officer and general manager of assessments, a role she has held since July 2017. The announcement came after current CEO Sangeet Chowfla announced his intention to step down from the position earlier this year, and an extensive search executed by a global executive recruiting firm. The GMAC board of directors unanimously voted to elect Jones, who will become GMAC’s fourth CEO as of October 1, 2022. “With more than a hundred interested candidates from around the world, the Board conducted extensive interviews and thorough evaluations over the past months and was thrilled to find the best person to l

GeoJunxion (GOJXN.AS) announces the booking of a series of Location Intelligence Service contracts with combined value of well over one Million Euro8.8.2022 18:00:00 CEST | Press release

Capelle aan den IJssel, The Netherlands – 8 August 2022 – GeoJunxion (GOJXN.AS) is pleased to announce the booking of a series of Location Intelligence Service contracts with combined value of well over one Million Euro. The first 40 days of the new Financial Year 2022/23 (1 July 2022 - 30 June 2023) have been particularly busy and exciting for the various teams in GeoJunxion. As result of this, GeoJunxion is pleased to announce the booking of a series of Location Intelligence Services for one of its major global IT customers, with a combined value well over one Million Euro. In response to an increasing demand for hyper local content, GeoJunxion has closed a series of extensions to existing service contracts and successfully completed the negotiations on a large new tailor-made Location Intelligence Service contract. These new contracts will convert into revenue over the next 3 to 6 months and will contribute substantially to the continued growth of the company’s top- and bottom-line.

INVITATION TO CONFERENCE CALL FOR DFDS' REPORT FOR Q2 20228.8.2022 17:48:27 CEST | Press release

INVESTOR NEWS no. 22 - 8 August 2022 DFDS expects to publish the report for Q2 2022 on 16 August 2022 at around 07:30 CET. Torben Carlsen, CEO, and Karina Deacon, CFO, will present the report on a live conference call. The presentation in English will be followed by a Q&A session. Investors, analysts and other interested parties are invited to take part. Date: 16 August 2022 Time: 10:00 CET Telephone: DK +45 35445577 UK +44 33 33000804 US +1 631 913 1422 Other international numbers: https://events-ftp.arkadin.com/ev/docs/NE_W2_TF_Events_International_Access_List.pdf Access code: 69612122# If you wish to take part in the audio conference, please dial up at least five minutes before the conference begins. It will start on time, and participants will be asked to register name and company name beforehand. The conference will be broadcast live on https://www.dfds.com/en/about and published there for future reference. Contact Søren Brøndholt Nielsen, IR +45 33 42 33 59 About DFDS DFDS provid

INVITATION TIL TELE-KONFERENCE OM DFDS' RAPPORT FOR 2. KVT. 20228.8.2022 17:48:27 CEST | pressemeddelelse

INVESTOR NEWS nr. 22 - 8. august 2022 DFDS’ kvartalsrapport for 2. kvt. 2022 forventes offentliggjort 16. august 2022 omkring kl. 07.30. Rapporten præsenteres på en tele-konference af Torben Carlsen, CEO og Karina Deacon, CFO. Efter præsentationen, der foregår på engelsk, vil der være mulighed for at stille spørgsmål. Investorer, analytikere og andre er velkommen til at deltage. Dato: 16. august 2022 Tidspunkt: Kl. 10.00 Telefonnumre: DK +45 35445577 UK +44 33 33000804 US +1 631 913 1422 Øvrige internationale telefonnumre: https://events-ftp.arkadin.com/ev/docs/NE_W2_TF_Events_International_Access_List.pdf Adgangskode: 69612122# Deltagere i tele-konferencen bedes ringe mindst fem minutter før starttidspunktet, da konferencen begynder rettidigt, og deltagere forinden skal registreres med navn og firmanavn. Tele-konferencen kan følges live på https://www.dfds.com/en/about og vil efterfølgende være tilgængelig på samme sted. Kontakt Søren Brøndholt Nielsen, IR +45 33 42 33 59 Om DFDS DFDS

Avance Gas Holding Ltd: 2022 Annual General Meeting8.8.2022 17:29:53 CEST | Press release

Hamilton, Bermuda 8 August 2022 - Avance Gas Holding Ltd (the "Company") advises that the 2022 Annual General Meeting of the Company will be held on September 30, 2022. The record date for voting at the Annual General Meeting is set to August 19, 2022. The notice, agenda and associated material will be distributed prior to the meeting. For further queries, please contact Executive Chairman: Øystein Kalleklev Tel: 47 23 11 40 00 About Avance Gas: Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carrier (VLGC) and operates a fleet of thirteen modern ships including two dual fuel LPG newbuidlings and has a further four dual fuel LPG newbuildings due for delivery in Q4 2022 and Q1-Q4 2023. For more information about Avance Gas, please visit www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities